What is HC Wainwright’s Estimate for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – HC Wainwright issued their Q1 2025 earnings per share estimates for Neurogene in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.85) for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.98) EPS and FY2025 earnings at ($3.68) EPS.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter.

Separately, William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research note on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $59.80.

Neurogene Stock Down 5.3 %

Shares of NASDAQ NGNE opened at $14.52 on Thursday. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49. The stock has a market cap of $215.69 million, a price-to-earnings ratio of -3.40 and a beta of 1.01. The company’s fifty day moving average is $16.88 and its 200-day moving average is $28.82.

Institutional Trading of Neurogene

Several hedge funds and other institutional investors have recently modified their holdings of NGNE. PNC Financial Services Group Inc. bought a new position in shares of Neurogene during the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. acquired a new position in Neurogene during the 4th quarter worth approximately $72,000. Virtus ETF Advisers LLC grew its stake in shares of Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after acquiring an additional 989 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after purchasing an additional 1,429 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Neurogene by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after purchasing an additional 1,397 shares in the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the transaction, the chief financial officer now directly owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.